Allergy:成年人哮喘风险与过敏性多重并发症和年龄的关系分析

2019-07-14 AlexYang MedSci原创

最近,有研究人员研究了过敏性多重并发症与成年人起始的哮喘的相关性,并考虑了过敏性疾病的数量和年龄的影响。研究是一个基于群体的研究,包括了1205名年龄大于30岁的成年人,他们均诊断为哮喘(年龄范围30-93)。另外,与性别、年龄和居住地匹配的对照包括了2050名。研究人员根据调查问卷确定了过敏性鼻炎(AR)、过敏性结膜炎(AC)和过敏性皮炎(AD)的情况。研究最后包括了1118个哮喘案例和阈值匹配

最近,有研究人员研究了过敏性多重并发症与成年人起始的哮喘的相关性,并考虑了过敏性疾病的数量和年龄的影响。

研究是一个基于群体的研究,包括了1205名年龄大于30岁的成年人,他们均诊断为哮喘(年龄范围30-93)。另外,与性别、年龄和居住地匹配的对照包括了2050名。研究人员根据调查问卷确定了过敏性鼻炎(AR)、过敏性结膜炎(AC)和过敏性皮炎(AD)的情况。研究最后包括了1118个哮喘案例和阈值匹配的1772个对照(平均年龄53(范围31-71岁),37%的为男性)。其中AR、AC和AD在哮喘患者中的报道的比例分别为50.2%、39.6%和33.8%,而在对照中的比例分别为26.1%、20.0%和23.5%。与非特应性过敏相比,成年人起始的哮喘与过敏性疾病数量的增加而增加;另外,1、2和3种过敏性疾病调整后哮喘的OR(CI 95%)分别为1.95 (1.52-2.49)、2.87 (2.19-3.77)和4.26 (3.07-5.90)。成年人起始的哮喘与不少于1种过敏性多重并发症的相关性随着年龄的增加而减少,在<50岁、50-62岁和大于62岁3个年龄段中相关性分别为 3.52 (2.51-4.94)、 2.44 (1.74-3.42)和1.68 (1.04-2.71)。

最后,研究人员指出,成年人起始的哮喘与过敏性疾病的数量呈现正相关关系,而随着年龄的增加相关性减少。

原始出处:

Toppila-Salmi S, Chanoine S, Karjalainen J et al. Risk of adult-onset asthma increases with the number of allergic multimorbidities and decreases with age. Allergy. 03 Jul 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047135, encodeId=8e9a204e13537, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 17 05:48:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023086, encodeId=d299202308660, content=<a href='/topic/show?id=d70839954ab' target=_blank style='color:#2F92EE;'>#哮喘风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39954, encryptionId=d70839954ab, topicName=哮喘风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Feb 29 00:48:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758139, encodeId=623a1e58139c2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Jan 24 02:48:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329258, encodeId=aefd132925898, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jul 16 02:48:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047135, encodeId=8e9a204e13537, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 17 05:48:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023086, encodeId=d299202308660, content=<a href='/topic/show?id=d70839954ab' target=_blank style='color:#2F92EE;'>#哮喘风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39954, encryptionId=d70839954ab, topicName=哮喘风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Feb 29 00:48:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758139, encodeId=623a1e58139c2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Jan 24 02:48:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329258, encodeId=aefd132925898, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jul 16 02:48:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047135, encodeId=8e9a204e13537, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 17 05:48:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023086, encodeId=d299202308660, content=<a href='/topic/show?id=d70839954ab' target=_blank style='color:#2F92EE;'>#哮喘风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39954, encryptionId=d70839954ab, topicName=哮喘风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Feb 29 00:48:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758139, encodeId=623a1e58139c2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Jan 24 02:48:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329258, encodeId=aefd132925898, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jul 16 02:48:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2020-01-24 丁鹏鹏
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047135, encodeId=8e9a204e13537, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 17 05:48:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023086, encodeId=d299202308660, content=<a href='/topic/show?id=d70839954ab' target=_blank style='color:#2F92EE;'>#哮喘风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39954, encryptionId=d70839954ab, topicName=哮喘风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Feb 29 00:48:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758139, encodeId=623a1e58139c2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Jan 24 02:48:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329258, encodeId=aefd132925898, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jul 16 02:48:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2019-07-16 膀胱癌

相关资讯

赛诺菲/Regeneron的IL-13单抗REGN3500治疗哮喘II期临床试验成功

赛诺菲和Regeneron宣布,其在研IL-33单抗REGN3500(SAR440340)治疗哮喘的II期临床试验中达到其主要和次要终点。

Nat Med:农场灰尘微生物或可缓解城市儿童哮喘

《自然-医学》本周在线发表的一项研究Farm-like indoor microbiota in non-farm homes protects children from asthma development发现,暴露在农场样房屋灰尘微生物组中可能与城市儿童的哮喘发生率降低相关。

2019 GINA哮喘指南发布!速来获取全文!

近日,全球哮喘防治倡议(GINA)发布了2019版哮喘指南,指南分为三大部分:① 成人、青少年和≥6岁儿童;② ≤5岁儿童;③ 临床实践转化。共有8个章节,涉及的内容有:哮喘的定义、描述和诊断;哮喘的评估;哮喘的治疗;哮喘加重的管理;哮喘、COPD和哮喘-慢阻肺重叠(ACO)的诊断和初始治疗;≤5岁儿童哮喘的诊断和管理;哮喘的一级预防;将哮喘管理策略落实到医疗系统。小咖对几个章节的核心要点(K

Allergy Asthma Proc:益生菌补充疗法在治疗哮喘、过敏性鼻炎和湿疹中的效果研究

益生菌补充疗法来改善过敏性疾病,包括儿童哮喘,已经在非常多的随机对照研究中有所探索。然而,关于益生菌补充疗法在怀孕和婴儿时期对哮喘和过敏性鼻炎发病率的影响结果还存在争议。最近,有研究人员系统性的探索了益生菌补充疗法对哮喘、过敏性鼻炎和湿疹发生和发展的影响。研究包括了17个随机对照研究,共包括了5264名儿童。研究发现,益生菌补充治疗后发展为哮喘的风险与对照相比没有显著的减少(风险比[RR] 0.8

中国学者登上《柳叶刀》:揭示我国哮喘真相!

近日,国际医学期刊《柳叶刀》发表中国学者完成的《中国成人哮喘流行状况、风险因素与疾病管理现状》研究结果,明确了中国成人哮喘流行状况:我国20岁及以上人群哮喘患病率为4.2%,成人患者总数达4570万,远超预估。